Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMOFIBM)

• Drug Name: LMT-X Drug Info
• Synonyms: Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 3	[1]
Alzheimer disease	8A20	Phase 3	[2]

• Cross-matching ID: TTD Drug ID: DMOFIBM

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Microtubule-associated protein tau (MAPT)	TTS87KH	TAU_HUMAN	Inhibitor	[3]
TAR DNA binding protein 43 (TARDBP)	TT9RZ03	TADBP_HUMAN	Inhibitor	[4]
Tau protein aggregation (TauA)	TTZGF8B	NOUNIPROTAC	Modulator	[5]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Microtubule-associated protein tau (MAPT)	DTT	MAPT	3.621	4	5.418	2.868

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

• The Studied Disease: Acute myeloid leukaemia
• ICD Disease Classification: 2A60

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Microtubule-associated protein tau (MAPT)	DTT	MAPT	3.76E-06	-0.22	-0.6

References

• [1] ClinicalTrials.gov (NCT01689246) Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease. U.S. National Institutes of Health.
• [2] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034429)
• [3] Clinical pipeline report, company report or official report of TauRx.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Successes and Failures for Drugs in Late-Stage Development for Alzheimer's Disease. Correction in: volume 31 on page 81.